LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Avita Therapeutics Inc

Fechado

4.18 -5.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.1

Máximo

4.42

Indicadores-chave

By Trading Economics

Rendimento

1.6M

-12M

Vendas

554K

18M

EPS

-0.536

Margem de lucro

-65.968

Funcionários

226

EBITDA

1.6M

-9.7M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+37.01% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

18M

142M

Abertura anterior

10.04

Fecho anterior

4.18

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Avita Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mar. de 2026, 22:42 UTC

Ganhos

Prudential PLC 2025 Adjusted Operating Profit Rises

17 de mar. de 2026, 21:40 UTC

Ganhos

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 de mar. de 2026, 23:56 UTC

Conversa de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 de mar. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 de mar. de 2026, 23:38 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 de mar. de 2026, 22:22 UTC

Conversa de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 de mar. de 2026, 22:07 UTC

Ganhos

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 de mar. de 2026, 22:05 UTC

Ganhos

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 de mar. de 2026, 22:04 UTC

Ganhos

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 de mar. de 2026, 22:03 UTC

Ganhos

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 de mar. de 2026, 21:26 UTC

Ganhos

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 de mar. de 2026, 21:09 UTC

Ganhos

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:07 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:06 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Net $757.2M >ATD.T

17 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Energy & Utilities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Avita Therapeutics Inc Previsão

Preço-alvo

By TipRanks

37.01% parte superior

Previsão para 12 meses

Média 6.33 USD  37.01%

Máximo 10 USD

Mínimo 3.5 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Avita Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

8.83 / 9.77Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat